Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $191
Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-Weight and raises the price target from $185 to $191.
Last updated: 2026-11-19 02:28:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Neurocrine Biosciences Inc. (NBIX) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $162.74, with a market capitalization of $16.73B and a P/E ratio of 23.91. Over the past 52 weeks, its price has ranged from $122.14 to $186.12. This page covers its latest market performance, valuation, price trends and company information.
$16.73B | |
$165.00 | |
$167.60 | |
$161.51 | |
$165.92 | |
1.13M | |
1.32M | |
23.91 | |
$186.12 | |
$122.14 | |
-- | |
2026-09-30 |
Neurocrine Biosciences Inc. (NBIX) last closed at $162.74 as of 2026-11-19 00:31:00, down 1.87% ($3.11) from the previous close of $165.92.
During the latest regular trading session, NBIX traded between $161.51 and $167.60, with a volume of 1.13M shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, Neurocrine Biosciences Inc. (NBIX) moved from $168.86 to $162.74, representing a decline of 3.62% ($6.12).
The stock traded between $161.51 and $174.59 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 1.28 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 63.5%
NBIX is currently trading at $162.74, placing it 63.5% of the way from its 52-week low of $122.14 to its 52-week high of $186.12. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 2,500 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Neurocrine Biosciences Inc. and NBIX stock.
Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-Weight and raises the price target from $185 to $191.
DelveInsight released a comprehensive competitive landscape report on GLP-1 receptor agonists and incretin-based therapies, covering 200+ pipeline drugs from 180+ active players. The report highlights approved drugs like MOUNJARO (tirzepatide) and OZEMPIC (semaglutide), with 30+ therapies in late-stage development and 60+ in mid/early stages. Key indications include obesity, type 2 diabetes, and cardiovascular outcomes. Recent developments include positive Phase III results for retatrutide, survodutide, and other dual/triple agonists from major pharmaceutical companies.
Eligible investors can buy real shares of Neurocrine Biosciences Inc. (NBIX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to NBIX, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between NBIX shares and USD.
NBIX Shares to USD
1.00 NBIX shares = 162.74 USD
Calculations are estimates based on the latest available price and are for reference only.